Drug Trial Radar · NCT07722741
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Sep 2029
Study completion Jun 2032
Sponsor
- Lead sponsor
- Geneos TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report, who were eligible to undergo definitive resection, have demonstrated laboratory, radiographic and/or pathologic high-risk criteria for recurrence (described under eligibility), have no evidence of disease (NED) as per MRI approximately 28 days post resection, and are able to provide a tissue sample for personalized neoantigen DNA vaccine development.
Conditions
- HCC
Interventions
GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporationBiological
delivered by intradermal injection and electroporation
Electroporation DeviceDevice
GNOS-PV02 + INO-9012 ID followed by electroporation
INO-9012Biological
cytokine interleukin-12 (IL-12), a vaccine adjuvant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-free survivalTime frame: Up to 5 years
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Emory University
Atlanta, Georgia · Not yet recruiting
Louisiana State University Health Sciences Center
New Orleans, Louisiana · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
University of Michigan
Ann Arbor, Michigan · Not yet recruiting
New York Presbyterian Hospital-Columbia University Irving Medical Center
New York, New York · Not yet recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Not yet recruiting
Auckland City Hospital (Te Toka Tumai)
Auckland, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.